Redeye reiterates its positive long-term stance to Heliospectra following a Q3-report overall in line with our expectations. The market sentiment has slightly shifted to cautiously optimistic, expecting a partial recovery in demand during the upcoming quarters. Our base case valuation remains unchanged.